Investigational drug · Phase 3
BAT5906
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Diabetic Macular Edema (DME), Neovascular (Wet) Age-related Macular Degeneration.
Phase 3Last checked: Nov 19, 2026Latest source record: Apr 7, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
5
Any phase or sponsor naming "BAT5906"
First trial start
2022
Jul 7, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BAT5906", any sponsor or status.
Conditions studied
As listed on its trial records.
- Diabetic Macular Edema (DME)
- Neovascular (Wet) Age-related Macular Degeneration
Approved drugs for the same conditions: Wet macular degeneration · Diabetic macular edema · Cardiovascular and metabolic · Ophthalmology
Largest trials
Live from ClinicalTrials.gov: studies naming "BAT5906" as an intervention, largest first.
- Efficacy Evaluation Study of BAT5906 and Lucentis® in Patients With Macular DegenerationPivotal-lookingCompleted
Bio-Thera SolutionsIndustry
NCT05439629 · 488 participants · Start Jul 7, 2022 · Primary completion Apr 22, 2025
Drug: BAT5906 injection; Lucentis · For: Neovascular (Wet) Age-related Macular Degeneration
Sites: Beijing, China; Changsha, China; Chongqing, China · 48 sites in all
- Efficacy Evaluation Study of BAT5906 and Lucentis® in Patients With Diabetic Macular EdemaPivotal-lookingRecruiting
Bio-Thera SolutionsIndustry
NCT07515079 · 406 participants (planned) · Start Oct 9, 2024 · Primary completion Apr 30, 2027
Drug: BAT5906 injection; Lucentis · For: Diabetic Macular Edema (DME)
Sites: Beijing, China; Chongqing, China; Lanzhou, China · 50 sites in all
Bio-Thera SolutionsIndustry
NCT04772105 · 60 participants · Start Oct 16, 2020 · Primary completion Nov 6, 2023
Drug: 2.5mg of BAT5906; 4.0mg of BAT5906 · For: Diabetic Macular Edema
Sites: Beijiang, China; Beijing, China; Bengbu, China · 19 sites in all
Bio-Thera SolutionsIndustry
NCT05141994 · 48 participants · Start Aug 26, 2020 · Primary completion Sep 6, 2022
Drug: 2.5mg of BAT5906; 4mg of BAT5906 · For: Wet Age-related Macular Degeneration
Sites: Beijing, China; Bengbu, China; Hangzhou, China · 16 sites in all
- A Phase I Clinical Trial of BAT5906 Injection in Patients With Wet Age-related Macular DegenerationCompleted
Bio-Thera SolutionsIndustry
NCT04151212 · 24 participants · Start Oct 30, 2018 · Primary completion Feb 28, 2021
Drug: BAT5906 injection · For: Age-related Macular Degeneration
Sites: Beijing, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Diabetic Macular Edema (DME)
- 4D-1503E10 vg, eyePhase 35 trials
4D Molecular Therapeutics · Neovascular Age-Related Macular Degeneration (nAMD), Diabetic Macular Edema (DME), Neovascular (Wet) Age-Related Macular Degeneration
- TiespectusEYE201, MK-8748Phase 35 trials
EyeBiotech Ltd. · Macular Degeneration, Age-Related Macular Degeneration, Choroidal Neovascularization
- EYP-1901Phase 34 trials
EyePoint Pharmaceuticals, Inc. · Diabetic Macular Edema, DME, Diabetic Macular Edema (DME)
- OLN324Phase 34 trials
Ollin Biosciences, Inc. · Diabetic Macular Edema (DME), Wet Age Related Macular Degeneration, Wet Age-related Macular Degeneration
- RemigromigEYE103, RestoretPhase 33 trials
EyeBiotech Ltd. · Diabetic Macular Edema (DME), Neovascular Age-Related Macular Degeneration (NVAMD), Branch Retinal Vein Occlusion (BRVO)
- Tabirafusp tedromerKSI-501Phase 32 trials
Kodiak Sciences Inc · Diabetic Macular Edema (DME), Wet Age-related Macular Degeneration
- RC28-EPhase 31 trial
RemeGen Co., Ltd. · Diabetic Macular Edema (DME), wAMD
- BGE-102Phase 22 trials
BioAge Labs, Inc. · Diabetic Macular Edema (DME), Obesity and Cardiovascular Risk
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.